Q-omics provides the consensus-scored PARD6BP1 profile across patient tissues and cancer cell-line models. PARD6BP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PARD6BP1 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, PARD6BP1 RNA expression shows 13,429 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, HNSC, and ESCA as cancer lineages where PARD6BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARD6BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARD6BP1 survival associations across molecular data types. PARD6BP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARD6BP1 RNA expression–survival associations across cancer types. High PARD6BP1 expression shows unfavorable associations in KIRC, THCA, KIRP and UVM, but favorable associations in BLCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PARD6BP1 RNA expression.
This table summarizes PARD6BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PARD6BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARD6BP1 shows higher tumor expression in HNSC, STAD, BRCA, KIRC, CHOL and COAD. The HNSC box plot shows higher PARD6BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p < 0.001).
This table shows molecular features associated with PARD6BP1 in patient tissues and cancer cell lines. In patient samples, PARD6BP1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
